PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer

CONCLUSION: The PDIS can be used as an effective prognostic model for predicting immunotherapy response to guide clinical decision-making.PMID:38466449 | PMC:PMC10927816 | DOI:10.1007/s00432-024-05626-4

Source: Clinical Breast Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Xueting Ren Hanxiao Cui Luyao Dai Lidan Chang Dandan Liu Wenyu Yan Xuyan Zhao Huafeng Kang Xiaobin Ma Source Type: research